Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Y / Y Equity Change	-	-	-	-	-65.22 %
Y / Y Net Income Change	489.41 %	-	-	-	-
Return On Equity	275.39 %	-	-	-	-

CHRS all Ratios >> Back to CHRS Management Effectiveness >> See Quarterly CHRS Return On Equity

You need to upgrade your Flash Player

Roe Comment

In (Dec 31 2025) ROE improved to 275.39 % compare to previous year, due to net income growth.

Financial Statements
Coherus Oncology Inc 's Equity	$ 61 Millions	Annual CHRS's Balance sheet
Coherus Oncology Inc 's Annual Income	$ 168 Millions	Annual CHRS's Income Statement
Where are CHRS's Income coming from?		Visit CHRS's Income by Segment

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.